Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study
Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.
Authors
- Jiayi Huang (ORCID: https://orcid.org/0009-0003-4353-2576)
- Song Lin (ORCID: https://orcid.org/0000-0002-7423-7217)
- Xiaofeng Xie
- Caiwen Du
- Liping Chen (ORCID: https://orcid.org/0000-0002-9494-9123)
- Xue Bai
- Xiaofeng Lan
- Xuelian Chen
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/bctt.s556110
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Sanming Project of Medicine in Shenzhen